1. Centers for Disease Control and Prevention [Internet]. HIV in the United States: At a Glance. 2016 [Cited 15 Nov 2017]. Available from: https://www.cdc.gov/hiv/statistics/overview/ataglance.html
2. Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial;JL Lennox;Ann Intern Med,2014
3. Ribaudo H, Wang H, Na L. A phase III comparative study of three non-nucleoside reverse transcriptase inhibitor (NNRTI)-sparing antiretroviral regimens for treatment-naïve HIV-1 infected volunteers (The ARDENT Study). A5257 Core Primary Analysis Report. September 24, 2013. (Data on file)
4. Red Book Online [Internet]. Micromedex 2.0 [Cited 15 Nov 2017]. Available from: http://www.micromedexsolutions.com/home/dispatch
5. Costs of adverse events among patients with HIV infection treated with nonnucleoside reverse transcriptase inhibitors;KN Simpson;HIV Med,2014